FORMA Therapeutics and Cancer Research Technology, Ltd (CRT) have announced the formation of two new virtual Asset Discovery and Development Companies (ADDCos) to represent the collective efforts of the consortium in the field of deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of […]
LMB In The News
Biologist Venki Ramakrishnan to lead Royal Society
The next president of the Royal Society will be the Nobel-winning LMB researcher Venki Ramakrishnan. He will succeed Paul Nurse in December 2015. After hearing of the confirmation, Venki told the BBC News that he was “very honoured” to be the society’s president elect. More…
Reaction map suggests meteorite chemistry route to life
LMB scientists have found a reaction network that they believe shows that ‘pretty much everyone’ working on life’s molecular origins is wrong – but also ‘right, in a sense’. Until now, the field has warred over which biomolecule, emerged first. But John Sutherland’s group found the different types may have appeared simultaneously. More…
In the beginning was the U1A protein: a personal reflection
LMB’s Kiyoshi Nagai looks back on his research on the spliceosome, RNA-protein interactions and the RNA recognition motif, U1A protein, for RNA journal. More…
British biotech Heptares snapped up by Japan’s Sosei in $400m deal
The Telegraph reports that the LMB spin-out company Heptares has been acquired by Japanese pharmaceutical company Soseito. The group’s research and development activities and 72 employees will remain in Hertfordshire, and Heptares will operate as an autonomous subsidiary to Sosei. Heptares is developing a string of drugs using a technology which can determine the precise […]
Lab land: architectural portrait of LMB
Architectural photographer, David Porter, explores LMB for Cambridge Business magazine, pages 65-69. More…